Biography and Research Information
OverviewAI-generated summary
Cade Richesin's research focuses on understanding the intricate interactions between cancer cells, the immune system, and the bone marrow microenvironment. His work investigates how melanoma tumor cells and immunotherapy can cooperatively reprogram bone marrow niches, leading to early hematopoietic dysfunction and the development of therapy-related myeloid neoplasms. Richesin also examines the comparative efficacy, durability, safety, and toxicity profiles of CAR T cell therapy versus bispecific antibodies in the treatment of B cell lymphomas, considering long-term outcomes. He has co-authored publications with researchers Hanne Jensen and Chinemerem M Emeasoba at the University of Arkansas.
Metrics
- Publications: 2
Selected Publications
-
1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles (2025)
Collaboration Network
Top Collaborators
Chinemerem M Emeasoba
University of Arkansas at Fayetteville
2 shared publications
In database
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
Chiugo Okoye
Northeast Georgia Medical Center (US)
2 shared publications
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
Hanne Jensen
University of Arkansas at Fayetteville
2 shared publications
In database
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
- 1073 Battle of the biologics a head to head review of CAR T cell therapy versus bispecific antibodies in B cell lymphomas balancing long term efficacy durability safety and toxicity profiles
Olusola Adetunji Oyedeji
Tenneco (United States) (US)
1 shared publication
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
Zeytun M Guyon
Washington Regional Medical Center (US)
1 shared publication
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
Chiamaka Elsie Nwachukwu
Tulane University (US)
1 shared publication
- 776 Melanoma tumor cells and immunotherapy cooperatively reprogram bone marrow niches to induce early hematopoietic dysfunction and therapy-related myeloid neoplasms
Similar Researchers
Based on overlapping research topics
A Almashayekh
University of Arkansas for Medical Sciences
Immune Response and Inflammation
CAR-T cell therapy research
Hematopoietic Stem Cell Transplantation
Mamatha Gaddam
University of Arkansas for Medical Sciences
Immune Response and Inflammation
CAR-T cell therapy research
Hematopoietic Stem Cell Transplantation
Eva Allen
University of Arkansas for Medical Sciences
Immune Response and Inflammation
CAR-T cell therapy research
Cancer Treatment and Pharmacology
Samuel L. Schach
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Carolina Schinke
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
CAR-T cell therapy research
lan J Tackett
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology